He T - Search Results

1

The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing.

Qian L, Li D, Ma L, He T, Qi F, Shen J, Lu XA. Qian L, et al. Among authors: he t. Cell Immunol. 2016 Jun-Jul;304-305:49-54. doi: 10.1016/j.cellimm.2016.03.003. Epub 2016 Mar 14. Cell Immunol. 2016. PMID: 26996927

2

MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2.

He T, Qi F, Jia L, Wang S, Song N, Guo L, Fu Y, Luo Y. He T, et al. J Pathol. 2014 Apr;232(5):499-508. doi: 10.1002/path.4324. Epub 2014 Feb 24. J Pathol. 2014. PMID: 24403060

3

Endostatin inhibits the tumorigenesis of hemangioendothelioma via downregulation of CXCL1.

Guo L, Song N, He T, Qi F, Zheng S, Xu XG, Fu Y, Chen HD, Luo Y. Guo L, et al. Among authors: he t. Mol Carcinog. 2015 Nov;54(11):1340-53. doi: 10.1002/mc.22210. Epub 2014 Aug 30. Mol Carcinog. 2015. PMID: 25175281

4

Nuclear-translocated endostatin downregulates hypoxia inducible factor-1α activation through interfering with Zn(II) homeostasis.

Guo L, Chen Y, He T, Qi F, Liu G, Fu Y, Rao C, Wang J, Luo Y. Guo L, et al. Among authors: he t. Mol Med Rep. 2015 May;11(5):3473-80. doi: 10.3892/mmr.2015.3223. Epub 2015 Jan 19. Mol Med Rep. 2015. PMID: 25607980

5

The miR-30 Family Inhibits Pulmonary Vascular Hyperpermeability in the Premetastatic Phase by Direct Targeting of Skp2.

Qi F, He T, Jia L, Song N, Guo L, Ma X, Wang C, Xu M, Fu Y, Li L, Luo Y. Qi F, et al. Among authors: he t. Clin Cancer Res. 2015 Jul 1;21(13):3071-80. doi: 10.1158/1078-0432.CCR-14-2785. Epub 2015 Mar 25. Clin Cancer Res. 2015. PMID: 25810374

6

Specific chemotherapeutic agents induce metastatic behaviour through stromal- and tumour-derived cytokine and angiogenic factor signalling.

Liu G, Chen Y, Qi F, Jia L, Lu XA, He T, Fu Y, Li L, Luo Y. Liu G, et al. Among authors: he t. J Pathol. 2015 Oct;237(2):190-202. doi: 10.1002/path.4564. Epub 2015 Jun 15. J Pathol. 2015. PMID: 25988668

7

Tumor cell-secreted angiogenin induces angiogenic activity of endothelial cells by suppressing miR-542-3p.

He T, Qi F, Jia L, Wang S, Wang C, Song N, Fu Y, Li L, Luo Y. He T, et al. Cancer Lett. 2015 Nov 1;368(1):115-125. doi: 10.1016/j.canlet.2015.07.036. Epub 2015 Aug 10. Cancer Lett. 2015. PMID: 26272182

8

Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma.

Bao F, Wan W, He T, Qi F, Liu G, Hu K, Lu XA, Yang P, Dong F, Wang J, Jing H. Bao F, et al. Among authors: he t. Cancer Gene Ther. 2019 Jul;26(7-8):248-255. doi: 10.1038/s41417-018-0073-7. Epub 2019 Jan 9. Cancer Gene Ther. 2019. PMID: 30622321 Clinical Trial.

9

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.

Ying Z, He T, Wang X, Zheng W, Lin N, Tu M, Xie Y, Ping L, Zhang C, Liu W, Deng L, Qi F, Ding Y, Lu XA, Song Y, Zhu J. Ying Z, et al. Among authors: he t. Mol Ther Oncolytics. 2019 Aug 28;15:60-68. doi: 10.1016/j.omto.2019.08.002. eCollection 2019 Dec 20. Mol Ther Oncolytics. 2019. PMID: 31650026 Free PMC article.

10

Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.

Zhang X, Lu XA, Yang J, Zhang G, Li J, Song L, Su Y, Shi Y, Zhang M, He J, Song D, Lv F, Li W, Wu Y, Wang H, Liu H, Zhou X, He T, Lu P. Zhang X, et al. Among authors: he t, he j. Blood Adv. 2020 May 26;4(10):2325-2338. doi: 10.1182/bloodadvances.2020001466. Blood Adv. 2020. PMID: 32453841 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,504 results

Search Page

Filters